Equities research analysts at Leerink Partnrs issued their Q1 2025 earnings estimates for Intellia Therapeutics in a research report issued to clients and investors on Thursday, February 27th. Leerink ...

Truist analyst Joon Lee lowered the firm’s price target on Intellia Therapeutics (NTLA) to $50 from $90 and keeps a Buy rating on the shares.

NEW YORK, NY / ACCESS Newswire / March 3, 2025 / If you suffered a loss on your Intellia Therapeutics, Inc. (NASDAQ:NTLA) investment and want to ...

Handelsbanken Fonder AB lifted its holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA – Free Report) by 7.1% in the 4th quarter, according to its most recent Form 13F filing with the Securities & ...

Intellia Therapeutics’ stock faces risks from market uncertainty and funding needs. Read why NTLA stock is downgraded to HOLD ...

Fintel reports that on February 28, 2025, JP Morgan downgraded their outlook for Intellia Therapeutics (NasdaqGM:NTLA) from ...

Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Intellia's technology platform specializes in Clustered Regularly Interspaced Short ...

Intellia Therapeutics, a leading clinical-stage gene editing company, has released its financial results for the fourth ...

Intellia Therapeutics reported better-than-expected results for the fourth quarter thanks to a boost in its collaboration ...

Intellia Therapeutics (NTLA) stock rises as company delivers promising Q4 2024 results with encouraging pipeline updates.

CAMBRIDGE, Mass., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based ...

Ginkgo already canceled its plans to move into Biofab1, a new 260,000-square-foot lab data center it's been building near its ...